Skip to main content
Erschienen in: Medical Oncology 5/2012

01.12.2012 | Original Paper

Increased expression of CD4+CD25+FOXP3+ regulatory T cells correlates with Epstein–Barr virus and has no impact on survival in patients with classical Hodgkin lymphoma in Brazil

verfasst von: Mariane C. G. Assis, Antonio H. F. M. Campos, Jose S. R. Oliveira, Fernando A. Soares, Joyce M. K. Silva, Priscilla B. Silva, Adriana D. Penna, Eni M. Souza, Otavio C. G. Baiocchi

Erschienen in: Medical Oncology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

The tumor microenvironment of classical Hodgkin lymphoma (cHL) is clearly responsible for the maintenance of the malignant Hodgkin-Reed–Sternberg (HRS) cells, and Epstein–Barr virus (EBV) has been shown to play a role in this immune evasion. EBV can increase the migration of CD4+CD25+FOXP3+ lymphocytes, named regulatory T cells (Tregs). In this study, we assessed the distribution and biological significance of Tregs in patients with cHL. Tissue microarrays were constructed using diagnostic biopsies available in 130 cHL patients and stained with CD4, CD8, CD25, and FOXP3 antibodies. For the present study, only cHL patients whose histology could be confirmed and EBV association established were studied. From the 130 cHL patients selected for this study, 56 were classified as EBV-related and 74 EBV non-related cHL. There were no association between clinical characteristics and the expression of Tregs. However, higher levels of Tregs correlated with EBV presence on HRS cells (p = 0.02), although it did not influence event-free survival (EFS) and overall survival (p = 0.98 and p = 0.59, respectively). This study demonstrates that Tregs expression correlates with EBV presence in HRS cells and has no impact on survival of patients with cHL. Further studies investigating the mechanisms in which EBV recruits Tregs to the tumor microenvironment will contribute not only to our understanding on the pathogenesis of cHL but also to the development of new therapeutic strategies.
Literatur
1.
Zurück zum Zitat Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283–97.PubMedCrossRef Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283–97.PubMedCrossRef
2.
Zurück zum Zitat Poppema S. Immunobiology and pathophysiology of Hodgkin lymphomas. Hematol Am Soc Hematol Educ Progr. 2005;1:231–238.CrossRef Poppema S. Immunobiology and pathophysiology of Hodgkin lymphomas. Hematol Am Soc Hematol Educ Progr. 2005;1:231–238.CrossRef
3.
Zurück zum Zitat Baumforth KR, Birgersdotter A, Reynolds GM, Wei W, Kapatai G, Flavell JR, Kalk E, Piper K, Lee S, Machado L, Hadley K, Sundblad A, Sjoberg J, Bjorkholm M, Porwit AA, Yap LF, Teo S, Grundy RG, Young LS, Ernberg I, Woodman CB, Murray PG. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin’s lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol. 2008;173:195–204.PubMedCrossRef Baumforth KR, Birgersdotter A, Reynolds GM, Wei W, Kapatai G, Flavell JR, Kalk E, Piper K, Lee S, Machado L, Hadley K, Sundblad A, Sjoberg J, Bjorkholm M, Porwit AA, Yap LF, Teo S, Grundy RG, Young LS, Ernberg I, Woodman CB, Murray PG. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin’s lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol. 2008;173:195–204.PubMedCrossRef
4.
Zurück zum Zitat Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 2006;66:5716–22.PubMedCrossRef Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 2006;66:5716–22.PubMedCrossRef
5.
Zurück zum Zitat Levings MK, Roncarlo MG. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol. 2000;106:S109–12.PubMedCrossRef Levings MK, Roncarlo MG. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol. 2000;106:S109–12.PubMedCrossRef
6.
Zurück zum Zitat Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.PubMedCrossRef Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.PubMedCrossRef
7.
Zurück zum Zitat Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3 + regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5:585–90.PubMed Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3 + regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5:585–90.PubMed
8.
Zurück zum Zitat Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3 + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica. 2008;93:193–200.PubMedCrossRef Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3 + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica. 2008;93:193–200.PubMedCrossRef
9.
Zurück zum Zitat Alvaro T, Lejeune M, Salvadó MT, Bosch R, García JF, Jaén J, Banham AH, Roncador G, Montalbán C, Piris MA. Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467–73.PubMedCrossRef Alvaro T, Lejeune M, Salvadó MT, Bosch R, García JF, Jaén J, Banham AH, Roncador G, Montalbán C, Piris MA. Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11:1467–73.PubMedCrossRef
10.
Zurück zum Zitat Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, Niedobitek G. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27:31–9.PubMedCrossRef Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, Niedobitek G. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27:31–9.PubMedCrossRef
11.
Zurück zum Zitat Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G. Hodgkin lymphoma: response assessment by revised international workshop criteria. Leuk Lymphoma. 2007;48:1539–47.PubMedCrossRef Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G. Hodgkin lymphoma: response assessment by revised international workshop criteria. Leuk Lymphoma. 2007;48:1539–47.PubMedCrossRef
12.
Zurück zum Zitat Cunha IW, Lopes A, Falzoni R, Soares FA. Sarcomas often express constitutive nitric oxide synthases (NOS) but infrequently inducible NOS. Appl Immunohistochem Mol Morphol. 2006;14:404–10.PubMedCrossRef Cunha IW, Lopes A, Falzoni R, Soares FA. Sarcomas often express constitutive nitric oxide synthases (NOS) but infrequently inducible NOS. Appl Immunohistochem Mol Morphol. 2006;14:404–10.PubMedCrossRef
13.
Zurück zum Zitat Campos AH, Aldred VL, Ribeiro KC, Vassallo J, Soares FA. Role of immunoexpression of nitric oxide synthases by Hodgkin and Reed-Sternberg cells on apoptosis deregulation and on clinical outcome of classical Hodgkin lymphoma. Mol Cell Biochem. 2009;321:95–102.PubMedCrossRef Campos AH, Aldred VL, Ribeiro KC, Vassallo J, Soares FA. Role of immunoexpression of nitric oxide synthases by Hodgkin and Reed-Sternberg cells on apoptosis deregulation and on clinical outcome of classical Hodgkin lymphoma. Mol Cell Biochem. 2009;321:95–102.PubMedCrossRef
14.
Zurück zum Zitat Murray PG, Young LS, Rowe M, Crocker J. Immunohistochemical demonstration of Epstein Barr virus encoded latent membrane protein in paraffin sections of Hodgkin’s disease. J Pathol. 1992;166:1–5.PubMedCrossRef Murray PG, Young LS, Rowe M, Crocker J. Immunohistochemical demonstration of Epstein Barr virus encoded latent membrane protein in paraffin sections of Hodgkin’s disease. J Pathol. 1992;166:1–5.PubMedCrossRef
15.
Zurück zum Zitat Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, Gill D, Marlton P, Seymour J, Khanna R. Expression of LAG-3 by tumorinfiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8 T-cell function in Hodgkin lymphoma patients. Blood. 2006;108:2280–9.PubMedCrossRef Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, Gill D, Marlton P, Seymour J, Khanna R. Expression of LAG-3 by tumorinfiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8 T-cell function in Hodgkin lymphoma patients. Blood. 2006;108:2280–9.PubMedCrossRef
16.
Zurück zum Zitat Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755–62.PubMedCrossRef Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755–62.PubMedCrossRef
17.
Zurück zum Zitat Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3 + regulatory T cells to granzyme B + cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol. 2007;128:958–65.PubMedCrossRef Kelley TW, Pohlman B, Elson P, Hsi ED. The ratio of FOXP3 + regulatory T cells to granzyme B + cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol. 2007;128:958–65.PubMedCrossRef
Metadaten
Titel
Increased expression of CD4+CD25+FOXP3+ regulatory T cells correlates with Epstein–Barr virus and has no impact on survival in patients with classical Hodgkin lymphoma in Brazil
verfasst von
Mariane C. G. Assis
Antonio H. F. M. Campos
Jose S. R. Oliveira
Fernando A. Soares
Joyce M. K. Silva
Priscilla B. Silva
Adriana D. Penna
Eni M. Souza
Otavio C. G. Baiocchi
Publikationsdatum
01.12.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 5/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0299-4

Weitere Artikel der Ausgabe 5/2012

Medical Oncology 5/2012 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.